VHL
| Cat Number: | MAB-94445 |
|---|---|
| Size: | 100 ug |
| Clone: | VHL19 |
| Concentration: | 1mg/ml |
| Host: | Ms |
| Isotype: | IgG |
| Immunogen: | Recombinant protein of human VHL |
| Reactivity: | Hu, Ms, Rt |
| Applications: | Western Blot: 1:500 - 1:1000 Immunohistochemistry: 1:50 - 1:100 Immunofluorescence: 1:50 - 1:100 Immunoprecipitation: 1:20 - 1:50 |
| Molecular: | 24kDa |
| Purification: | Aff. Pur. |
| Synonyms: | VHL; HRCA1; RCA1; VHL1; pVHL; von Hippel-Linda u tumor suppressor |
| Background: | Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. |
| Form: | Liquid |
| Buffer: | PBS with 0.02% sodium azide, pH7.3 |
| Storage: | At 2-8°C for short term storage, and at -20°C for longer term. Avoid freeze and thaw cycles |
